伊立替康联合替吉奥治疗进展期食管鳞癌

目的评价伊立替康联合替吉奥在治疗进展期食管鳞癌中的疗效和毒副反应。方法 47例进展期食管鳞癌患者均接受伊立替康和替吉奥治疗。结果 47例患者中45例可评价疗效,有效率为37.8%,疾病控制率为73.3%；中位疾病进展时间为5个月,中位生存时间为9个月,1 a生存率为22.2%。主要毒副反应为骨髓抑制、腹泻、恶心、呕吐等,经对症处理后均可缓解。结论伊立替康联合替吉奥在治疗进展期食管鳞癌中有一定的疗效,且毒副反应轻。

Efficacy of Irinotecan Combined with S-1 for Patients with Advanced Esophageal Squamous-celled Cancer

Objective To investigate the efficacy and toxicities of irinotecan combined with S-1 for patients with advanced esophageal squamous-celled cancer. Methods All the 47 patients with advanced esophageal squamouscelled cancer received irinotecan and S-1. Results Of all the 47 patients,the efficacy of 45 patients could be evaluated,the response rate was 37. 8%,the disease control rate was 73. 3%; the overall median time to tumor progression was 5 months,the overall median overall survival was 9 months,and the 1-year survival rate was 22. 2%. The major toxicities were bone marrow suppression,diarrhea,nausea and vomiting,but were mild. Conclusion Irinotecan combined with S-1 is effective and tolerable for the patients with advanced esophageal squamous-celled cancer.